We have located links that may give you full text access.
Controversies in terlipressin and transplantation in the United States: How do we MELD the two?
Liver Transplantation 2024 March 28
Hepatorenal syndrome-acute kidney injury (HRS-AKI) is a severe complication of cirrhosis that carries a poor prognosis. The recent Food and Drug Administration approval of terlipressin has substantial implications for managing HRS-AKI and liver allocation in the United States (US). Terlipressin has been available in Europe for over a decade, and several countries have adapted policy changes such as Model for End-Stage Liver Disease (MELD) score "lock" for HRS-AKI. In this article, we outline the European experience with terlipressin use and explore the question of whether terlipressin treatment for HRS-AKI should qualify for MELD score "lock" in the US in those who respond to therapy. Arguments for the MELD lock include protecting waitlist priority for terlipressin responders or partial responders who may miss offers due to MELD reduction in the terlipressin treatment window. Arguments against MELD lock include the fact that terlipressin may produce a durable response and improve overall survival, and that equitable access to terlipressin is not guaranteed due to cost and availability. We subsequently discuss proposed next steps for studying terlipressin implementation in the US. A successful approach will require the involvement of all major stakeholders and the mobilization of our transplant community to spearhead research in this area.
Full text links
Related Resources
Trending Papers
Mineralocorticoid Receptor Antagonists in Heart Failure: An Update.Circulation. Heart Failure 2024 November 25
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app